Published in J Virol on November 01, 2002
Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol (2003) 1.37
A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol (2008) 1.16
A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODN-based vaginal microbicide. J Clin Invest (2006) 1.16
Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production. J Virol (2006) 1.16
Innate and adaptive immune responses to herpes simplex virus. Viruses (2009) 1.14
Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc (2007) 1.12
Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha. Immunology (2006) 1.09
NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection. J Virol (2005) 1.08
FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling. PLoS Pathog (2008) 1.06
Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. J Virol (2006) 1.04
Commensal bacteria modulate innate immune responses of vaginal epithelial cell multilayer cultures. PLoS One (2012) 1.01
Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia. J Virol (2003) 0.95
Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection. J Virol (2010) 0.94
Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization. Clin Vaccine Immunol (2010) 0.94
Mucosal delivery of CpG oligodeoxynucleotides expands functional dendritic cells and macrophages in the vagina. Immunology (2005) 0.94
Effects of particle size on toll-like receptor 9-mediated cytokine profiles. Biomaterials (2010) 0.92
CpG oligodeoxynucleotides improve the survival of pregnant and fetal mice following Listeria monocytogenes infection. Infect Immun (2004) 0.88
Salmonella enterica serovar typhimurium exploits Toll-like receptor signaling during the host-pathogen interaction. Infect Immun (2009) 0.88
FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J (2009) 0.86
Tweaking Innate Immunity: the Promise of Innate Immunologicals As Anti-infectives. Can J Infect Dis Med Microbiol (2006) 0.86
RNA-dependent protein kinase is required for alpha-1 interferon transgene-induced resistance to genital herpes simplex virus type 2. J Virol (2005) 0.85
Expression of toll-like receptors in genital tract tissues from normal and HIV-infected men. Am J Reprod Immunol (2011) 0.82
Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2. PLoS One (2013) 0.82
Broad-spectrum drugs against viral agents. Int J Mol Sci (2008) 0.81
Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy. Future Microbiol (2010) 0.80
Evasion of early antiviral responses by herpes simplex viruses. Mediators Inflamm (2015) 0.80
Contribution of nitric oxide to CpG-mediated protection against Listeria monocytogenes. Infect Immun (2005) 0.79
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2001) 9.19
Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med (1997) 7.59
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A (2001) 5.02
Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA (2001) 4.54
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 4.12
Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 3.82
Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol (2001) 3.64
Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol (2001) 3.34
Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol (1996) 2.74
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet (1994) 2.53
Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol (2001) 2.49
Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J Virol (2001) 2.43
Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology (1997) 2.37
T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol (1998) 2.31
Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis (1982) 2.16
Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol (1996) 2.06
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05
Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol (1991) 2.02
Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology (1995) 1.86
Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol (2001) 1.84
Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol (1998) 1.77
Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun (1998) 1.67
Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis (1997) 1.60
Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch Dermatol (2001) 1.48
Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2. J Gen Virol (1990) 1.48
Detection and direct typing of herpes simplex virus by polymerase chain reaction. Med Microbiol Immunol (1990) 1.47
A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann Intern Med (1995) 1.39
Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol (1992) 1.34
Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmission. J Virol (2001) 1.31
Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol (2000) 1.10
Protective immunity against HSV-2 in the mouse vagina. J Reprod Immunol (1997) 1.10
Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis (2001) 1.07
Role of polymorphonuclear leukocytes in resolution of HSV-2 infection of the mouse vagina. J Reprod Immunol (2001) 1.03
Natural killer cells prevent direct anterior-to-posterior spread of herpes simplex virus type 1 in the eye. Invest Ophthalmol Vis Sci (2000) 1.00
Effect of undecylenic acid as a topical microbicide against genital herpes infection in mice and guinea pigs. Antiviral Res (1999) 0.96
Current recommendations for the treatment of genital herpes. Drugs (2000) 0.93
The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit Rev Immunol (2001) 0.93
Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis (2001) 0.91
The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis (1994) 0.89
Reduced herpes simplex virus type 1 latency in Flt-3 ligand-treated mice is associated with enhanced numbers of natural killer and dendritic cells. Immunology (2001) 0.88
Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences. Invest Ophthalmol Vis Sci (2000) 0.87
Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol (2001) 0.87
Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol (2000) 0.86
Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. Springer Semin Immunopathol (2000) 0.85
Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine (2001) 0.84
CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. J Virol (2001) 0.83
Mechanism of action of imiquimod 5% cream in the treatment of anogenital warts. Prim Care Update Ob Gyns (1998) 0.81
Herpes simplex virus latency and nucleoside analogues. Antiviral Res (1999) 0.81
Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Am J Respir Crit Care Med (2001) 0.80
Limiting the spread of genital herpes. Scand J Infect Dis Suppl (1996) 0.80
Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs. Antiviral Res (1988) 0.80
Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. Antiviral Res (1999) 0.79
Surface warfare against pathogens using mucosal vaccines. Nat Biotechnol (1997) 0.76
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis (2012) 2.05
Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol (2003) 1.65
A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine (2003) 1.60
Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun (2006) 1.59
Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. Am J Respir Crit Care Med (2014) 1.53
Determination of acute lung injury after repeated platelet transfusions. Blood (2010) 1.51
Clearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanisms. J Virol (2005) 1.45
High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex Transm Dis (2009) 1.38
Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun (2007) 1.37
Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis (2003) 1.28
Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med (2010) 1.21
Effect of hospital-based comprehensive care clinic on health costs for Medicaid-insured medically complex children. Arch Pediatr Adolesc Med (2011) 1.19
Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis (2005) 1.17
Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis (2005) 1.16
Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol (2004) 1.16
Entry of inflammatory cells into the mouse vagina following application of candidate microbicides: comparison of detergent-based and sulfated polymer-based agents. Sex Transm Dis (2002) 1.15
Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol (2002) 1.14
Application of optical coherence tomography for monitoring changes in cervicovaginal epithelial morphology in macaques: potential for assessment of microbicide safety. Sex Transm Dis (2008) 1.13
Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha. Immunology (2006) 1.09
Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis (2005) 1.08
Parental acceptance of adolescent vaccines within school-based health centres. Herpes (2005) 1.04
VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine (2007) 1.04
Investigation of translocation, DNA unwinding, and protein displacement by NS3h, the helicase domain from the hepatitis C virus helicase. Biochemistry (2010) 0.98
Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol (2004) 0.98
Perceptions of reimbursement for clinical trial participation. J Empir Res Hum Res Ethics (2011) 0.98
Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob Agents Chemother (2005) 0.97
Assessment and management of pulmonary alveolar proteinosis in a reference center. Orphanet J Rare Dis (2013) 0.97
Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol (2005) 0.96
Local and systemic effects of intranodally injected CpG-C immunostimulatory-oligodeoxyribonucleotides in macaques. J Immunol (2006) 0.96
Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand. J Leukoc Biol (2007) 0.95
Current thinking on genital herpes. Curr Opin Infect Dis (2014) 0.92
Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. Sex Transm Dis (2004) 0.91
Polymyxin B enhances ISS-mediated immune responses across multiple species. Cell Immunol (2004) 0.91
Optical coherence tomography compared with colposcopy for assessment of vaginal epithelial damage: a randomized controlled trial. Obstet Gynecol (2011) 0.91
New frontiers in meningococcal vaccines. Expert Rev Vaccines (2011) 0.91
Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells. Nucleic Acids Res (2003) 0.91
The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease. Hum Vaccin Immunother (2014) 0.91
Topical microbicide use by adolescent girls: concerns about timing, efficacy, and safety. Sex Transm Dis (2003) 0.90
Modification of primary and recurrent genital herpes in guinea pigs by passive immunization. J Gen Virol (2002) 0.90
Neonatal herpes should be a reportable disease. Sex Transm Dis (2005) 0.89
Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes? Sex Transm Dis (2003) 0.88
Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs (2006) 0.87
New biomedical approaches for sexually transmitted infection prevention: vaccines and microbicides. Adolesc Med Clin (2004) 0.87
Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines. Clin Vaccine Immunol (2009) 0.86
Adolescent issues associated with knowledge of and access to topical microbicides. J Womens Health (Larchmt) (2004) 0.86
Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol (2013) 0.86
Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J Clin Invest (2015) 0.85
Benzalkonium chloride causes colposcopic changes and increased susceptibility to genital herpes infection in mice. Sex Transm Dis (2010) 0.85
Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males. Clin Infect Dis (2010) 0.84
A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production. Eur J Immunol (2003) 0.83
Immunostimulatory DNA as a vaccine adjuvant. Expert Rev Vaccines (2007) 0.83
Prevention of mother-to-child transmission of viral infections. Curr Probl Pediatr Adolesc Health Care (2008) 0.83
Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease. Hum Vaccin Immunother (2012) 0.81
A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo. Clin Immunol (2005) 0.81
Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity. Mol Pharm (2012) 0.81
Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials. Sex Transm Dis (2012) 0.80
Increased prevalence of luminal narrowing and stricturing identified by enterography in pediatric Crohn's disease patients with elevated granulocyte-macrophage colony stimulating factor autoantibodies. Inflamm Bowel Dis (2013) 0.79
Pediatrics and herpes simplex virus vaccines. Semin Pediatr Infect Dis (2005) 0.79
Treatment with a novel topical nanoemulsion (NB-001) speeds time to healing of recurrent cold sores. J Drugs Dermatol (2012) 0.78
Parental acceptability of vaccines for sexually transmitted infections. Arch Pediatr Adolesc Med (2005) 0.78
Blueprint for success: translating innovations from the field of palliative medicine to the medical-legal partnership. J Leg Med (2014) 0.78
Non-exclusivity in adolescent girls' romantic relationships. Sex Transm Dis (2003) 0.78
An adjunct exercise program for serious mental illness: who chooses to participate and is it feasible? Community Ment Health J (2012) 0.78
Prevalence of herpes simplex virus types 1 and 2 among children and adolescents attending a sexual abuse clinic. Pediatr Infect Dis J (2006) 0.76
Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1. J Allergy Clin Immunol (2006) 0.76
Effect of candidate vaginally-applied microbicide compounds on recognition of antigen by CD4+ and CD8+ T lymphocytes. Biol Reprod (2004) 0.76
Effects of candidate vaginally-applied microbicide compounds on innate immune cells. J Reprod Immunol (2005) 0.76
Local induction of a specific Th1 immune response by allergen linked immunostimulatory DNA in the nasal explants of ragweed-allergic subjects. Allergol Int (2009) 0.76
Estimating the population prevalence of HPV. JAMA (2007) 0.75
Parental reasons for utilization of an urban pediatric emergency department during the 2009 H1N1 influenza epidemic. Pediatr Emerg Care (2011) 0.75
Screening for neonatal herpes: physicians' descriptions of discussions with parents. Herpes (2002) 0.75
Predictors of herpes simplex virus type 2 antibody positivity among persons with no history of genital herpes. Sex Transm Dis (2004) 0.75
A framework for faculty development. J Pediatr (2011) 0.75
Incorporation of 28-d Leptocheirus plumulosus toxicity data in a sediment weight-of-evidence framework. Ecotoxicol Environ Saf (2009) 0.75
Familial Association of Granulocyte-Macrophage Colony Stimulating Factor Autoantibodies in Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr (2017) 0.75
The relationship between STD locus of control and STD acquisition among adolescent girls. Adolescence (2002) 0.75
The MLP vital sign: assessing and managing legal needs in the healthcare setting. J Leg Med (2014) 0.75
Vaccines for sexually transmitted infections. Pediatr Ann (2005) 0.75
Reducing the stigma of herpes simplex virus infection: lessons from an online video contest. Sex Health (2012) 0.75